Antibiotic Susceptibility Pattern of Burkholderia cepacia Complex and Stenotrophomonas maltophilia: A 5-year Analysis

Bhavana, Malavalli Venkatesh; Joshi, Sangeeta; Adhikary, Ranjeeta; Beena, Hosdurg Bhaskar

doi:10.4103/ijmm.ijmm_16_236

Cited by 4 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, host factors like immunocompromising states, pre-existing lung diseases, prolonged hospital stay, and broad spectrum antibiotics and hardware play a notable role in making the situation even more alarming. 3,4 Burkholderia cepacia is the etiological agent of several hospital-acquired infections, including types of pneumonia, particularly in patients with pre-existing lung diseases, e.g. cystic fibrosis, bacteremia, urinary tract infections, infections of the musculoskeletal system, skin and soft tissue infections and rarely shunt related meningitis.…”

Section: Introductionmentioning

confidence: 99%

Burkholderia Cepacia: An Emerging Superbug in Intensive Care Unit Settings of Tertiary Care Hospitals in Pakistan

Irfan

Amer²,

Mirza³

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the frequency, risk factors, and antibiotic susceptibility pattern of Burkholderia cepacia isolates from clinical specimens in a Pakistani tertiary care hospital. Study Design: Cross-sectional Study Place and Duration of Study: Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Jul 2017 to Jun 2021. Methodology: The Burkholderia cepacia strains were isolated from clinical samples by routine microbiological methods. In our laboratory, the identification and antimicrobial susceptibility testing of the isolate were made by API 20NE and VITEK-2 Automated Microbiology Analyzer. Results: Four hundred and nineteen (419) str5-ains of Burkholderia cepacia were isolated during the study period. Among them,277(66.1%) and 57(13.6%) isolates were from blood cultures and lower respiratory tracts, respectively. The antibiotic-resistant rates of the isolates of Minocycline, Cotrimoxazole, Levofloxacin, Meropenem, and Ceftazidime were 13(3.1%), 26(6.2%), 49(11.6%),74(17.6%) and 118(28.16%) respectively. Conclusion: We observed a gradual increase in the frequency of isolation. A surge in antimicrobial resistance was also seen during the study period underscoring the need for rigorous implementation of antimicrobial stewardship programs and infection control practices.

show abstract

Section: Introductionmentioning

confidence: 99%

Burkholderia Cepacia: An Emerging Superbug in Intensive Care Unit Settings of Tertiary Care Hospitals in Pakistan

Irfan

Amer²,

Mirza³

et al. 2022

PAFMJ

View full text Add to dashboard Cite

show abstract

In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

Flamm

Shortridge

Castanheira

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We evaluated the activity of minocycline and comparator agents against a large number of Stenotrophomonas maltophilia (n = 1,289), Acinetobacter baumannii-Acinetobacter calcoaceticus species complex (n = 1,081), and Burkholderia cepacia complex (n = 101) isolates collected from 2014 to 2018 from 87 U.S. medical centers spanning all 9 census divisions. The isolates were collected primarily from hospitalized patients with pneumonia (1,632 isolates; 66.0% overall), skin and skin structure infections (354 isolates; 14.3% overall), bloodstream infections (266 isolates; 10.8% overall), urinary tract infections (126 isolates; 5.1% overall), intra-abdominal infections (61 isolates; 2.5% overall), and other infections (32 isolates; 1.3% overall). Against the A. baumannii-A. calcoaceticus species complex, colistin was the most active agent, exhibiting MIC50/90 values at ≤0.5/2 μg/ml and 92.4% susceptibility. Minocycline ranked second in activity, with MIC50/90 values at 0.25/8 μg/ml and susceptibility at 85.7%. Activity for these two agents was reduced against extensively drug-resistant and multidrug-resistant isolates of the Acinetobacter baumannii-Acinetobacter calcoaceticus species complex. Only two agents showed high levels of activity (susceptibility, >90%) against S. maltophilia, minocycline (MIC50/90, 0.5/2 μg/ml; 99.5% susceptible) and trimethoprim-sulfamethoxazole (MIC50/90, ≤0.5/1 μg/ml; 94.6% susceptible). Minocycline was active against 92.8% (MIC90, 4 μg/ml) of trimethoprim-sulfamethoxazole-resistant S. maltophilia isolates. Various agents exhibited susceptibility rates of nearly 90% against the B. cepacia complex isolates; these were trimethoprim-sulfamethoxazole (MIC50/90, ≤0.5/2 μg/ml; 93.1% susceptible), ceftazidime (MIC50/90, 2/8 μg/ml; 91.0% susceptible), meropenem (MIC50/90, 2/8 μg/ml; 89.1% susceptible), and minocycline (MIC50/90, 2/8 μg/ml; 88.1% susceptible). These results indicate that minocycline is among the most active agents for these three problematic potential pathogen groups when tested against U.S. isolates.

show abstract

Advances in the Microbiology of Stenotrophomonas maltophilia

2021

View full text Add to dashboard Cite

show abstract

Antibiotic Susceptibility Pattern of Burkholderia cepacia Complex and Stenotrophomonas maltophilia: A 5-year Analysis

Cited by 4 publications

References 4 publications

Burkholderia Cepacia: An Emerging Superbug in Intensive Care Unit Settings of Tertiary Care Hospitals in Pakistan

Burkholderia Cepacia: An Emerging Superbug in Intensive Care Unit Settings of Tertiary Care Hospitals in Pakistan

In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

Advances in the Microbiology of Stenotrophomonas maltophilia

Contact Info

Product

Resources

About